Isis Reports Positive Interim Phase 2 Data on ISIS-APOCIII Rx

Isis Pharmaceuticals, Inc.

announced interim data from an ongoing Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides.  These data were presented today by Dr. Daniel Gaudet at a PACE session occurring concurrently with the European Society of Cardiology in Amsterdam.  In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions of up to 79 percent in apolipoprotein C-III (apoC-III) and up to 75 percent in triglycerides.  In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant mean increases of up to 57 percent in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol.  Patients also achieved up to 89 percent mean reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles.  (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)   "Patients with very high levels of triglycerides experience a significant number of health problems, including type 2 diabetes, obesity, cardiovascular disease and, for patients with severely elevated triglycerides, pancreatitis.  For these patients, there are very limited treatment options and what is needed is a